A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis

Completed · Phase 3 · Has a placebo group

Conditions studied: Uveitis, Anterior, Panuveitis

In brief

The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious anterior uveitis

Key facts

Study ID

NCT00404885

Run by

Lux Biosciences, Inc.

People needed

108

Starts

2007-01-01

Expected to finish

2009-05-01

Last updated by the study team

2012-06-22

Who can join

Age: 13 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented history of non-infectious anterior, anterior and intermediate- or panuveitis
• Currently uncontrolled uveitis for a minimum of 2 weeks despite use of oral and/or topical corticosteroid,or subjects who are intolerant of local corticosteroid therapy due to the development of an ocular hypertensive response or subjects for whom oral corticosteroid is contraindicated.
• Grade of 2+ or higher for anterior chamber cells at time of enrollment
• Considered by the investigator to require corticosteroid-sparing therapy.
• Subjects not planning to undergo elective ocular surgery during the study

You may not qualify if…

• Uveitis of infectious etiology
• Presence of an ocular toxoplasmosis scar
• An immune suppression regimen that includes an alkylating agent within the previous 90 days

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States
• Retinal Consultants of Arizona — Phoenix, Arizona, United States
• University of Illinois - Chicago — Chicago, Illinois, United States
• Wilmer Eye Institute — Baltimore, Maryland, United States
• Massachusetts Eye and Ear Infirmary — Boston, Massachusetts, United States
• Massachusetts Eye Research and Surgery Institute — Cambridge, Massachusetts, United States
• Associated Retinal Consultants, PC — Grand Rapids, Michigan, United States
• Tauber Eye Center — Kansas City, Missouri, United States
• New York Eye & Ear Hospital — New York, New York, United States
• Duke University Eye Center, Erwin Road — Durham, North Carolina, United States
• Oregon Health Sciences University — Portland, Oregon, United States
• Brian B. Berger, MD, P.A. — Austin, Texas, United States
• Retina & Uveitis Consultants of Texas — San Antonio, Texas, United States
• Viginia Eye Consultants — Norfolk, Virginia, United States
• Universitätsklinik für Augenheilkunde — Salzburg, Austria
• Klinik für Augenheilkunde, Dept. of Ophthalmology — Vienna, Austria
• McGill University Health Center — Montreal, Quebec, Canada
• Hôpital Pitié Salpétrière, Service d'Ophtalmologie — Paris, France
• Universitätsklinikum Freiburg — Freiburg im Breisgau, Germany
• Augenklinik der Universität Heidelberg — Heidelberg, Germany
• St. Franziskus-Hospital — Münster, Germany
• Universitätsklinikum Tübingen — Tübingen, Germany
• L V Prasad Eye Institute — Hyderabaad, Andhra Pradesh, India
• Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology — Madurai, Tamil Nadu, India
• Vittala International Institute of Ophthalmology — Bangalore, India

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.